Last updated: February 20, 2026
Locoid, a topical corticosteroid medication containing hydrocortisone butyrate, is supplied by several pharmaceutical companies globally. This medication is used primarily to treat inflammatory skin conditions such as eczema, dermatitis, and psoriasis.
Major Suppliers and Manufacturers
1. GlaxoSmithKline (GSK)
- Product Name: Locoid
- Formulations: Cream, ointment, lotion, and scalp application
- Regions: Europe, North America, Asia
- Market Share: Leading supplier in European markets and one of the main sources worldwide
- Approval: Approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
2. MediGene AG
- Product Name: Hydrocortison Butyrate Locoid (generic)
- Formulations: Cream, ointment
- Regions: Primarily European markets
- Partnerships: Supplies to generic manufacturers
3. Zentiva (formerly Lupin)
- Product Name: Hydrocortisone Butyrate topical formulations
- Regions: Central and Eastern Europe
- Market Focus: Generic versions of Locoid
4. Sandoz (Novartis division)
- Product Name: Generic hydrocortisone butyrate formulations
- Regions: North America, Europe
- Market Segment: Generic drug producer, supplies to pharmacies and hospitals
5. Generic Manufacturers in India and China
- A broad range of local and regional manufacturers produce hydrocortisone butyrate topical formulations. Examples includeSun Pharma, Aurobindo Pharma, and Zhejiang Huahai Pharmaceutical.
- These companies supply generic Locoid-equivalent products mainly for markets in Asia, Africa, and Latin America.
Supply Chain Notes
- Supply can fluctuate based on regulatory approvals, manufacturing capacity, and regional patent statuses.
- GSK's Locoid remains the brand leader globally, with generics increasing market penetration.
- Suppliers primarily produce topical formulations in cream, ointment, lotion, and scalp solutions.
Regulatory and Patent Landscape
- GSK's patent on Locoid expired in several jurisdictions, facilitating generic competition from 2015 onward.
- Companies must meet local regulatory standards—such as FDA approval in the U.S. or EMA approval in Europe—to market hydrocortisone butyrate products.
Key Procurement Considerations
- Confirm regional availability and approval timelines.
- Evaluate supplier certifications—GMP compliance is critical.
- Compare pricing for branded Locoid versus generics.
- Assess supply chain stability amid regulatory changes and patent expirations.
Summary Table of Main Suppliers
| Supplier |
Product Type |
Regions |
Market Focus |
Notes |
| GSK |
Branded Locoid |
Global |
Leading brand |
Strong market presence, patent expiry in some regions |
| MediGene AG |
Generic products |
Europe |
Generic supply |
Focused on European markets |
| Zentiva |
Generics |
Central/Eastern Europe |
Win in regional markets |
Competitive pricing |
| Sandoz |
Generics |
North America, Europe |
Major generics player |
Produces multiple formulations |
| Sun Pharma |
Generics |
Asia, Africa |
Cost-effective supply |
Expanding into emerging markets |
Summary
Market supply of Locoid primarily depends on a balance between branded GSK products and various regional generic manufacturers. The patent expiration in key markets has increased generic competition, affecting pricing and availability.
Key Takeaways
- GSK remains the primary supplier for branded Locoid globally.
- Generics from regional manufacturers dominate in emerging markets due to cost advantages.
- Regulatory approvals significantly influence regional availability.
- Patent expirations have increased generic competition since 2015.
- Supply chain stability depends on GMP certification, regional approvals, and patent status.
FAQs
1. Are there regulatory restrictions on importing Locoid from different regions?
Yes. Regulatory restrictions vary; imports require compliance with local drug approval standards and may involve tariffs or registration requirements.
2. What factors influence the choice between branded Locoid and generics?
Cost, regulatory approval, availability, and supplier reliability shape purchasing decisions.
3. How does patent expiration impact supply?
Patent expiration enables generic competition, which typically results in increased supply and reduced prices.
4. Are all generic versions of hydrocortisone butyrate bioequivalent to Locoid?
Yes, provided they meet regional bioequivalence and manufacturing standards.
5. What are the primary risks in sourcing Locoid?
Regulatory delays, supply chain disruptions, quality compliance failures, and patent litigation can affect procurement stability.
References
[1] European Medicines Agency (EMA). (2022). Marketing authorisations for hydrocortisone butyrate. EMA.
[2] U.S. Food and Drug Administration (FDA). (2022). Drug approvals and generics. FDA.
[3] IMS Health. (2021). Global topical corticosteroid market analysis.
[4] GSK official website. (2022). Product information for Locoid.
[5] Indian Pharmaceutical Market Report. (2021). Indian generics manufacturers.
